angina pectoris
Conditions
Interventions
(1)At least a week before surgery, patients will be randomly assigned to B-group or non B-group. (2)B-group will receive bisoprolol fumarate (Maintate) at least a week before surgery. Dosage of of b
=70bpm: Maintate 2.5mg/day, HR<
70bpm: Maintate 1.25mg/day) (3)Both group will receive Maintate 1.25mg/day from postoperative day1 and dosage will increase up to 2.5mg/day depends on patients'
tolerance.
(1) At least a week before surgery, patients will be randomly assigned to B-group or non B-group. Non B-group will receive no bisoprolol fumarate (Maintate) before surgery. (2) Both
tolerance.
Sponsors
Department of cardiovascular surgery, Mitsubishi Kyoto Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subjects were patients who were scheduled to undergo isolated CABG. Including criteria as follows, (1) Patients without beta-blocker administration at the registration (2) Left ventricular ejection fraction > 50% (3) Age>=20 years (4) Informed consent was provided by each patient after receiving an explanation about the study.
Exclusion criteria
Exclusion criteria: (1) Emergency surgery cases (2) Patients with a history of chronic atrial fibrillation, paroximal atrial fibrillation, 2nd- 3rd degree atrioventricular block, sinus bradycardia (3) Prior pacemaker implantation (4) Patients with beta-blocker administration at the registration (5) Pregnant woman (6) Patients who were considered not adequate to be included in the study by an attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| new onset of postoperative atrial fibrillation during hospitalization | — |
Secondary
| Measure | Time frame |
|---|---|
| all cause of death, cardiovascular death, myocardial infarction, pace maker implantation, cardiac arrest | — |
Countries
Japan
Contacts
Public ContactHiroaki Osada
Mitsubishi Kyoto Hospital Cardiovascular Surgery
Outcome results
None listed